T1	Participants 63 150	postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy
T2	Participants 319 426	postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT).
T3	Participants 435 563	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine with or without oxaliplatin
T4	Participants 674 711	Two hundred and twenty-eight patients
T5	Participants 2092 2117	patients with AA genotype
T6	Participants 2003 2032	cases with GG or GA genotypes
